Daré Bioscience, Inc.

NasdaqCM:DARE Stock Report

Market Cap: US$25.9m

Daré Bioscience Future Growth

Future criteria checks 5/6

Daré Bioscience is forecast to grow earnings and revenue by 71.4% and 78.4% per annum respectively while EPS is expected to grow by 65.1% per annum.

Key information

71.4%

Earnings growth rate

65.1%

EPS growth rate

Pharmaceuticals earnings growth23.9%
Revenue growth rate78.4%
Future return on equityn/a
Analyst coverage

Low

Last updated16 Dec 2024

Recent future growth updates

Recent updates

We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate

Nov 07
We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Jul 21
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?

Mar 12
Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?

Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms

Oct 17

Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive

Oct 10

Dare Bioscience reports positive progress for cream for female sexual arousal disorder

Aug 29

Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy

Jun 30

Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?

Apr 02
Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?

Diving Back Into Daré Bioscience Again

Jan 07

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Nov 26
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Daré Bioscience's DARE-BV1 shows positive action in late-stage bacterial vaginosis study

Apr 26

Diving Into Daré Bioscience

Jan 31

Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching

Dec 22
Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching

Dare Bioscience EPS misses by $0.06

Nov 12

Earnings and Revenue Growth Forecasts

NasdaqCM:DARE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202621-21N/AN/A2
12/31/20252-20N/AN/A4
12/31/20241-3N/AN/A4
9/30/20242-4-9-8N/A
6/30/20243-7-11-10N/A
3/31/20243-29-30-30N/A
12/31/20233-30-39-39N/A
9/30/20231-41-37-37N/A
6/30/2023N/A-40-20-20N/A
3/31/202310-31-22-22N/A
12/31/202210-31-18-18N/A
9/30/202210-25-22-22N/A
6/30/202210-30-29-29N/A
3/31/2022N/A-40-33-33N/A
12/31/2021N/A-39-29-29N/A
9/30/2021N/A-38-28-28N/A
6/30/2021N/A-33-35-35N/A
3/31/2021N/A-30-27-27N/A
12/31/2020N/A-27-25-25N/A
9/30/2020N/A-23-20-20N/A
6/30/2020N/A-19-18-18N/A
3/31/2020N/A-16-17-17N/A
12/31/2019N/A-15-13-13N/A
9/30/2019N/A-14-12-12N/A
6/30/2019N/A-13-12-12N/A
3/31/2019N/A-12-12-11N/A
12/31/2018N/A-17-11-10N/A
9/30/2018N/A-23-9-9N/A
6/30/2018N/A-22N/A-7N/A
3/31/2018N/A-19N/A-5N/A
12/31/2017N/A-12N/A-3N/A
9/30/2017N/A-3N/A-2N/A
6/30/2017N/A-1N/A0N/A
3/31/2017N/A-1N/A0N/A
12/31/2016N/A-1N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DARE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: DARE is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: DARE is expected to become profitable in the next 3 years.

Revenue vs Market: DARE's revenue (78.4% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: DARE's revenue (78.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if DARE's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 11:10
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Daré Bioscience, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Brian Kemp DolliverBrookline Capital Markets
Douglas TsaoH.C. Wainwright & Co.